Bayer Asset Gives Roivant Sciences’ New ‘Vant’ a Shot at Besting a United Therapeutics Lung Drug

Roivant Sciences subsidiary Pulmovant is on track for a Phase 2 test of mosliciguat as a treatment for pulmonary hypertension associated with interstitial lung disease. The inhaled drug offers a different mechanism of action and less burdensome dosing compared to United Therapeutics’ blockbuster PH-ILD drug, Tyvaso. The post Bayer Asset Gives Roivant Sciences’ New ‘Vant’…

Read More

Trump Vowed To End Surprise Medical Bills. The Office Working on That Just Got Slashed.

As President Donald Trump wrapped up his first term in 2020, he signed legislation to protect Americans from surprise medical bills. “This must end,” Trump said. “We’re going to hold insurance companies and hospitals totally accountable.” But the president’s wide-ranging push to slash government spending, led by billionaire Elon Musk, is weakening the federal office…

Read More